{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-047844","form_type":"8-K/A","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.037862+00:00","generated_at":"2026-05-21T13:55:35.448660+00:00","sec_items":["2.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tvardi Q1 2025 net loss $9.6M, cash burn $7.7M; going concern doubt persists","bullets":["Net loss $9.6M ($0.50 dil EPS) vs $4.2M loss in Q1 2024; accumulated deficit $101.8M.","Revenue nil; operating expenses $4.35M (R&D $3.1M, G&A $1.2M).","Cash & equivalents $11.4M, short-term investments $10.9M at March 31; cash used in ops $7.7M.","Convertible notes $35.8M; other expense $5.5M from fair value change on notes.","Merger closed April 15, 2025 provided $23.8M cash; substantial doubt about going concern pre-merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-047844","json":"https://secwatch.observer/filing/0001104659-25-047844.json","markdown":"https://secwatch.observer/filing/0001104659-25-047844.md","text":"https://secwatch.observer/filing/0001104659-25-047844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925047844/0001104659-25-047844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925047844/tm2514727d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T13:55:35.448660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}